Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced it will report first quarter 2026 financial results on Monday, May 4, 2026, after the close of the U.S. financial markets. The Company will ...
We just covered the Billionaire Joe Edelman’s 10 Stock Picks with Huge Upside Potential and Travere Therapeutics, Inc.
An established sales force and payer authorization criteria will fuel a fast launch for Travere Therapeutics’ Filspari in its ...
Travere Therapeutics rated a Buy after Filspari’s FDA approval for FSGS—only therapy available. Read TVTX's valuation upside, ...
Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.
Pitt Street Research and Euroz Hartleys have released research notes on Dimerix highlighting upside potential as progresses ...
Shrugging off an earlier phase 3 disappointment, Travere’s Filspari has become the first FDA-approved treatment for rare kidney disease focal segmental glomerulosclerosis (FSGS). The company's already ...
Johnson & Johnson will present at the Bernstein's 42nd Annual Strategic Decisions Conference on Wednesday, May 27th, 2026.
Strand Therapeutics, a clinical-stage biotechnology company pioneering programmable mRNA medicines, today announced it will present preclinical data from its in vivo CAR-T program at the 2026 American ...
The Summers Value Fund LP returned 6.7% net in 2025, trailing Russell 2000 Index ETF, which returned 12.7%, and Russell 2000 ...
In a report released today, Allison Bratzel from Piper Sandler maintained a Buy rating on Ardelyx, with a price target of $16.00.
"AstraZeneca to seek accelerated approval of Ultomirisin in IgAN on Phase III data" was originally created and published by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results